Share Price and Basic Stock Data
Last Updated: December 9, 2025, 10:57 pm
| PEG Ratio | 18.97 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fischer Medical Ventures Ltd operates in the chemicals sector, specifically focusing on inorganic materials. Recently, the company’s financial performance has shown a noteworthy recovery trajectory. Sales for the financial year ending March 2024 stood at ₹21 Cr, a significant uptick from zero in the previous year. However, this momentum appears inconsistent when examining quarterly numbers, with a sharp rise to ₹49.17 Cr in March 2025, followed by fluctuations in subsequent quarters. The trailing twelve months (TTM) revenue reached ₹124 Cr, indicating a growing operational footprint. Yet, the underlying pattern suggests that while the company is ramping up sales, it faces challenges in maintaining steady revenue growth, as evidenced by the drop to ₹10.12 Cr in June 2024 before rebounding again. This inconsistency may raise questions about the sustainability of its growth trajectory.
Profitability and Efficiency Metrics
Profitability metrics for Fischer Medical Ventures reflect a company grappling with operational efficiency. The operating profit margin (OPM) stood at a modest 3% for the year ending March 2025, considerably lower than the sector average. More telling is the quarterly OPM, which saw a peak of 18.17% in June 2025, but prior figures showed significant fluctuations, including a negative margin in June 2024. Net profit for FY 2025 was reported at ₹1 Cr, down from ₹2 Cr in FY 2024, illustrating a decline in profitability. The interest coverage ratio (ICR) of 9.80x indicates that while the company can cover its interest obligations comfortably, its overall profitability remains constrained. Additionally, the cash conversion cycle (CCC) has improved to 205 days in March 2025, suggesting better inventory and receivables management, yet it still raises concerns about liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fischer Medical Ventures presents a mixed picture. With total borrowings reported at ₹30 Cr against ₹295 Cr in reserves, the company appears to be in a relatively stable position regarding leverage. The debt-to-equity ratio is a modest 0.17, which suggests that the company is not heavily reliant on debt for financing its operations. However, the price-to-book value ratio of 16.97x indicates that the stock may be overvalued compared to its book value of ₹52.90 per share. This could signal investor caution, especially as the company has yet to establish consistent profitability. The return on equity (ROE) of 0.70% and return on capital employed (ROCE) of 1.08% are considerably lower than industry benchmarks, indicating that while the company has built a substantial reserve, its ability to generate returns on that capital is lacking.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fischer Medical Ventures offers insights into investor sentiment and confidence. Promoters hold 61.80% of the company, a significant reduction from over 74% in previous quarters, which could imply a dilution of their stake or a strategic shift in ownership. Meanwhile, foreign institutional investors (FIIs) have gradually increased their stake to 5.57%, reflecting a growing interest from external players. Domestic institutional investors (DIIs) and the public hold minor stakes of 1.42% and 31.22%, respectively. The increase in the number of shareholders to 13,054 indicates a growing retail interest in the company. However, the high promoter holding coupled with the decline might raise concerns about management’s commitment to driving shareholder value, especially in light of the company’s inconsistent financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Fischer Medical Ventures faces a complex landscape. While the increase in sales and the improvement in cash conversion cycles suggest potential for growth, the volatility in profits and margins raises red flags for cautious investors. The reliance on a small number of institutional investors and high promoter stakes can be a double-edged sword; it may provide stability but could also hinder broader market confidence. Additionally, the company’s ability to navigate operational inefficiencies and maintain consistent profitability will be crucial in determining its future trajectory. Investors should remain vigilant regarding the company’s performance and the broader market dynamics affecting the chemicals sector. Ultimately, while there are opportunities for upside, the risks associated with fluctuating financials and market perceptions warrant careful consideration before making investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fischer Medical Ventures Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,897 Cr. | 44.8 | 125/40.8 | 144 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 14.9 Cr. | 29.9 | 47.2/25.8 | 64.9 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 203 Cr. | 260 | 410/238 | 12.1 | 211 | 3.08 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 6,207 Cr. | 499 | 728/408 | 30.3 | 157 | 0.60 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 324 Cr. | 415 | 536/376 | 15.8 | 144 | 0.72 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 4,605.25 Cr | 541.43 | 171.15 | 160.00 | 0.51% | 13.95% | 10.65% | 7.00 |
Quarterly Result
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 20.79 | 10.12 | 39.66 | 11.75 | 49.17 | 23.44 |
| Expenses | 0.00 | 18.28 | 10.33 | 39.16 | 11.38 | 46.68 | 19.18 |
| Operating Profit | 0.00 | 2.51 | -0.21 | 0.50 | 0.37 | 2.49 | 4.26 |
| OPM % | 12.07% | -2.08% | 1.26% | 3.15% | 5.06% | 18.17% | |
| Other Income | 0.00 | 0.47 | 0.69 | 0.05 | 0.38 | 0.06 | 7.36 |
| Interest | 0.00 | 0.05 | 0.13 | 0.05 | 0.07 | 0.23 | 0.67 |
| Depreciation | 0.00 | 0.18 | 0.28 | 0.29 | 0.56 | 0.51 | 0.77 |
| Profit before tax | 0.00 | 2.75 | 0.07 | 0.21 | 0.12 | 1.81 | 10.18 |
| Tax % | 6.18% | 271.43% | -38.10% | 350.00% | 27.62% | 50.79% | |
| Net Profit | 0.00 | 2.59 | -0.12 | 0.29 | -0.29 | 1.31 | 5.01 |
| EPS in Rs | 0.00 | 0.48 | -0.02 | 0.05 | -0.05 | 0.21 | 0.77 |
Last Updated: August 19, 2025, 3:40 pm
Below is a detailed analysis of the quarterly data for Fischer Medical Ventures Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.44 Cr.. The value appears to be declining and may need further review. It has decreased from 49.17 Cr. (Mar 2025) to 23.44 Cr., marking a decrease of 25.73 Cr..
- For Expenses, as of Jun 2025, the value is 19.18 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 46.68 Cr. (Mar 2025) to 19.18 Cr., marking a decrease of 27.50 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.26 Cr.. The value appears strong and on an upward trend. It has increased from 2.49 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 1.77 Cr..
- For OPM %, as of Jun 2025, the value is 18.17%. The value appears strong and on an upward trend. It has increased from 5.06% (Mar 2025) to 18.17%, marking an increase of 13.11%.
- For Other Income, as of Jun 2025, the value is 7.36 Cr.. The value appears strong and on an upward trend. It has increased from 0.06 Cr. (Mar 2025) to 7.36 Cr., marking an increase of 7.30 Cr..
- For Interest, as of Jun 2025, the value is 0.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.23 Cr. (Mar 2025) to 0.67 Cr., marking an increase of 0.44 Cr..
- For Depreciation, as of Jun 2025, the value is 0.77 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.51 Cr. (Mar 2025) to 0.77 Cr., marking an increase of 0.26 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.18 Cr.. The value appears strong and on an upward trend. It has increased from 1.81 Cr. (Mar 2025) to 10.18 Cr., marking an increase of 8.37 Cr..
- For Tax %, as of Jun 2025, the value is 50.79%. The value appears to be increasing, which may not be favorable. It has increased from 27.62% (Mar 2025) to 50.79%, marking an increase of 23.17%.
- For Net Profit, as of Jun 2025, the value is 5.01 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 5.01 Cr., marking an increase of 3.70 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.77. The value appears strong and on an upward trend. It has increased from 0.21 (Mar 2025) to 0.77, marking an increase of 0.56.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:21 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 0 | 21 | 111 | 124 |
| Expenses | 0 | 19 | 108 | 116 |
| Operating Profit | 0 | 2 | 3 | 8 |
| OPM % | 11% | 9% | 3% | 6% |
| Other Income | 0 | 0 | 1 | 8 |
| Interest | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 2 | 2 |
| Profit before tax | 0 | 2 | 2 | 12 |
| Tax % | 13% | 45% | ||
| Net Profit | -0 | 2 | 1 | 6 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.10 |
| Dividend Payout % | 0% | 0% | 22% |
YoY Net Profit Growth
| Year | 2024-2025 |
|---|---|
| YoY Net Profit Growth (%) | -50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% |
Fischer Medical Ventures Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2024-2025 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 428% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 78% |
| 5 Years: | 91% |
| 3 Years: | 149% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | -0 | 28 | 274 | 295 |
| Borrowings | 1 | 2 | 85 | 30 |
| Other Liabilities | 0 | 4 | 34 | 77 |
| Total Liabilities | 0 | 86 | 457 | 468 |
| Fixed Assets | 0 | 15 | 24 | 31 |
| CWIP | 0 | 0 | 1 | 2 |
| Investments | 0 | 1 | 11 | 121 |
| Other Assets | 0 | 70 | 421 | 313 |
| Total Assets | 0 | 86 | 457 | 468 |
Below is a detailed analysis of the balance sheet data for Fischer Medical Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 295.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2025) to 295.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 85.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 55.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 77.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 468.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 313.00 Cr.. The value appears to be declining and may need further review. It has decreased from 421.00 Cr. (Mar 2025) to 313.00 Cr., marking a decrease of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 468.00 Cr.. The value appears strong and on an upward trend. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (295.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Free Cash Flow | -1.00 | 0.00 | -82.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 345 | 398 | 251 |
| Inventory Days | 36 | ||
| Days Payable | 82 | ||
| Cash Conversion Cycle | 345 | 398 | 205 |
| Working Capital Days | 324 | 498 | 107 |
| ROCE % | 5% | 1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.08 | 1.65 | -2.12 |
| Diluted EPS (Rs.) | 0.08 | 1.08 | -2.12 |
| Cash EPS (Rs.) | 0.52 | 0.37 | -2.12 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Revenue From Operations / Share (Rs.) | 17.35 | 3.92 | 10.44 |
| PBDIT / Share (Rs.) | 0.75 | 0.44 | 0.88 |
| PBIT / Share (Rs.) | 0.50 | 0.40 | 0.88 |
| PBT / Share (Rs.) | 0.42 | 0.39 | -0.07 |
| Net Profit / Share (Rs.) | 0.26 | 0.34 | -2.12 |
| NP After MI And SOA / Share (Rs.) | 0.18 | 0.34 | -2.12 |
| PBDIT Margin (%) | 4.36 | 11.25 | 8.46 |
| PBIT Margin (%) | 2.89 | 10.38 | 8.46 |
| PBT Margin (%) | 2.44 | 10.06 | -0.72 |
| Net Profit Margin (%) | 1.53 | 8.75 | -20.33 |
| NP After MI And SOA Margin (%) | 1.09 | 8.75 | -20.33 |
| Return on Networth / Equity (%) | 0.35 | 2.26 | 0.00 |
| Return on Capital Employeed (%) | 0.90 | 2.64 | 4.97 |
| Return On Assets (%) | 0.26 | 2.12 | -10.32 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -2.15 |
| Total Debt / Equity (X) | 0.17 | 0.00 | -2.15 |
| Asset Turnover Ratio (%) | 0.40 | 0.48 | 0.00 |
| Current Ratio (X) | 3.59 | 18.37 | 5.18 |
| Quick Ratio (X) | 3.50 | 17.20 | 5.18 |
| Inventory Turnover Ratio (X) | 16.23 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 9.80 | 34.92 | 0.92 |
| Interest Coverage Ratio (Post Tax) (X) | 4.43 | 28.19 | -1.21 |
| Enterprise Value (Cr.) | 5536.85 | 3303.93 | 1.98 |
| EV / Net Operating Revenue (X) | 50.02 | 157.47 | 11.03 |
| EV / EBITDA (X) | 1145.02 | 1399.44 | 130.31 |
| MarketCap / Net Operating Revenue (X) | 51.74 | 159.28 | 8.05 |
| Price / BV (X) | 16.97 | 41.20 | -5.43 |
| Price / Net Operating Revenue (X) | 51.74 | 159.31 | 8.05 |
| EarningsYield | 0.00 | 0.00 | -0.02 |
After reviewing the key financial ratios for Fischer Medical Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.65 (Mar 24) to 0.08, marking a decrease of 1.57.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.08 (Mar 24) to 0.08, marking a decrease of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.52, marking an increase of 0.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 17.35. It has increased from 3.92 (Mar 24) to 17.35, marking an increase of 13.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 2. It has increased from 0.44 (Mar 24) to 0.75, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.50, marking an increase of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.39 (Mar 24) to 0.42, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.26, marking a decrease of 0.08.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.18, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 4.36. This value is below the healthy minimum of 10. It has decreased from 11.25 (Mar 24) to 4.36, marking a decrease of 6.89.
- For PBIT Margin (%), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 10. It has decreased from 10.38 (Mar 24) to 2.89, marking a decrease of 7.49.
- For PBT Margin (%), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 10. It has decreased from 10.06 (Mar 24) to 2.44, marking a decrease of 7.62.
- For Net Profit Margin (%), as of Mar 25, the value is 1.53. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 1.53, marking a decrease of 7.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 8. It has decreased from 8.75 (Mar 24) to 1.09, marking a decrease of 7.66.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 15. It has decreased from 2.26 (Mar 24) to 0.35, marking a decrease of 1.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 10. It has decreased from 2.64 (Mar 24) to 0.90, marking a decrease of 1.74.
- For Return On Assets (%), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 24) to 0.26, marking a decrease of 1.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.48 (Mar 24) to 0.40, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has decreased from 18.37 (Mar 24) to 3.59, marking a decrease of 14.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 2. It has decreased from 17.20 (Mar 24) to 3.50, marking a decrease of 13.70.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 16.23. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 16.23, marking an increase of 16.23.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.80. This value is within the healthy range. It has decreased from 34.92 (Mar 24) to 9.80, marking a decrease of 25.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 28.19 (Mar 24) to 4.43, marking a decrease of 23.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,536.85. It has increased from 3,303.93 (Mar 24) to 5,536.85, marking an increase of 2,232.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 50.02. This value exceeds the healthy maximum of 3. It has decreased from 157.47 (Mar 24) to 50.02, marking a decrease of 107.45.
- For EV / EBITDA (X), as of Mar 25, the value is 1,145.02. This value exceeds the healthy maximum of 15. It has decreased from 1,399.44 (Mar 24) to 1,145.02, marking a decrease of 254.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.28 (Mar 24) to 51.74, marking a decrease of 107.54.
- For Price / BV (X), as of Mar 25, the value is 16.97. This value exceeds the healthy maximum of 3. It has decreased from 41.20 (Mar 24) to 16.97, marking a decrease of 24.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.31 (Mar 24) to 51.74, marking a decrease of 107.57.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fischer Medical Ventures Ltd:
- Net Profit Margin: 1.53%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.9% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.35% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.5
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 144 (Industry average Stock P/E: 155.59)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.53%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Survey No. 480/2 AP Medtech Zone, Nadupura Village, Vishakapatnam Andhra Pradesh 530032 | cs@fischermv.com https://www.fischermv.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ravindran Govindan | Chairman & Managing Director |
| Ms. Svetlana Rao | Whole Time Executive Director |
| Mr. Sanjay Jayantilal Jain | Independent Director |
| Mr. Jaya Ankur Singhania | Independent Director |
| Mr. Khairy Jamaluddin Abu Bakkar | Independent Director |
| Mr. Roberto M Pagdanganan | Independent Director |
FAQ
What is the intrinsic value of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd's intrinsic value (as of 10 December 2025) is 4.48 which is 90.00% lower the current market price of 44.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,897 Cr. market cap, FY2025-2026 high/low of 125/40.8, reserves of ₹295 Cr, and liabilities of 468 Cr.
What is the Market Cap of Fischer Medical Ventures Ltd?
The Market Cap of Fischer Medical Ventures Ltd is 2,897 Cr..
What is the current Stock Price of Fischer Medical Ventures Ltd as on 10 December 2025?
The current stock price of Fischer Medical Ventures Ltd as on 10 December 2025 is 44.8.
What is the High / Low of Fischer Medical Ventures Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fischer Medical Ventures Ltd stocks is 125/40.8.
What is the Stock P/E of Fischer Medical Ventures Ltd?
The Stock P/E of Fischer Medical Ventures Ltd is 144.
What is the Book Value of Fischer Medical Ventures Ltd?
The Book Value of Fischer Medical Ventures Ltd is 5.55.
What is the Dividend Yield of Fischer Medical Ventures Ltd?
The Dividend Yield of Fischer Medical Ventures Ltd is 0.01 %.
What is the ROCE of Fischer Medical Ventures Ltd?
The ROCE of Fischer Medical Ventures Ltd is 1.08 %.
What is the ROE of Fischer Medical Ventures Ltd?
The ROE of Fischer Medical Ventures Ltd is 0.70 %.
What is the Face Value of Fischer Medical Ventures Ltd?
The Face Value of Fischer Medical Ventures Ltd is 1.00.